Conference: ISPOR Europe 2026
日期： November 8 - 11, 2026
地点： Vienna, Austria
展位： 304
Meet our experts at this year’s ISPOR Europe event to learn how Certara’s integrated capabilities support value demonstration throughout drug development.
- RWE studies – data acquisition, design, execution and analysis
- Modeling and simulation – advanced modeling (ITCs, ML-based models and surrogate endpoint analysis) and health economic models (cost effectiveness, budget impact) to support strategic positioning and health technology assessment (HTA) value dossiers
Join us for our Issue Panels and Posters
Issue Panels
Tuesday, 10 November, 16:45 - 17:45
Most Favoured Nation Pricing: Will International Price Alignment Improve Affordability or Restrict Access to Innovation? Insights from Central and Eastern Europe
Wednesday, 11 November, 8:00 - 9:00
Preparing CEE Countries for JCA: Aligning European HTA Standards with National Access Decisions
Wednesday, 11 November, 10:00 - 11:00
Can CEE Healthcare Systems Afford Innovation Without Reforming Procurement and Financing Models?
海报
Monday, 9 November 10:30 – 13:30 – Poster session 1
Annual Out-of-Pocket Caps and Equity-Driven Patient Cost-Sharing Across European Healthcare Systems: A 30-Country Comparative Analysis.
Access to Modern Therapies for Prostate Cancer Patients in Central and Eastern Europe (CEE): A Cross-Country Assessment of HTA and Reimbursement Pathways.
Monday, 9 November 16:30 – 19:00 – Poster session 2
Overall Survival of Sugemalimab Plus Chemotherapy Versus First-Line PD-1/PD-L1 Inhibitor Regimens in Metastatic NSCLC: An Ethnicity-Adjusted Indirect Treatment Comparison.
Tuesday, 10 November, 13:45-14:45
Research Podium Session “New Forces Shaping Global Pricing”
US Most Favoured Nation Pricing and EU Joint Clinical Assessment: A CEE-Weighted Pulse Check on Launch Strategy, Evidence Generation and Access Risk
Wednesday 11 November, 9:00 – 11:30 – Poster Session 5
Financial Solutions – Patient Payment Models and Alternative Forms of Financing.
Why Do Similar Clinical Data Result in Different HTA Conclusions and Reimbursement Decisions? The Case of Semaglutide and Tirzepatide in Obesity.
A Novel Registry-Database Linkage to Enable Real-World Evidence Generation in Rare Diseases: Algorithm Development and Validation for Myotonic Dystrophy Type 1 in the French SNDS.
精选推荐
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
